<DOC>
	<DOCNO>NCT01068652</DOCNO>
	<brief_summary>This trial conduct Africa . The aim clinical trial investigate effect 50 week treatment different intensified insulin administration ( combination fix dose metformin ) blood sugar control subject type 2 diabetes inadequately control oral anti-diabetic drug ( OADs ) .</brief_summary>
	<brief_title>Effect Different Insulin Administrations , All Combination With Metformin , Glycaemic Control Subjects With Type 2 Diabetes Inadequately Controlled Oral Anti-diabetic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) Diagnosed type 2 diabetes ( WHO 1999 criterion ) Currently treat suboptimal daily dose OADs ( mono combination therapy ) least 6 month Male female age least 18 year old HbA1c least 7.0 % maximum 11.0 % subject treat metformin monotherapy , maximum 10 % subject treat OAD combination therapy BMI maximum 40 kg/m^2 Able willing perform selfmonitoring plasma glucose accord protocol keep diary Able willing treat 4 insulin injection per day Known suspect allergy trial product ( ) relate product Previous participation trial . Participation define randomisation Females childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method ( adequate contraceptive measure require local law practice ) Participated another clinical trial receive investigational drug within last week prior present trial Impaired hepatic function define alanine aminotransferase ( ALT ) alkaline phosphatase ( ALP ) least 2.5 time upper reference limit Impaired renal function define serumcreatinine least 1.3 mg/dL ( least 115 mmol/L ) males least 1.2 mg/dL ( least 106 mmol/L ) females Subject clinically significant , active ( past 12 month ) cardiovascular history ( include history myocardial infarction ( MI ) , arrhythmias conduction delay ECG , unstable angina , decompensated heart failure ( New York Heart Association class III IV ) Severe uncontrolled treat untreated hypertension ( sit systolic blood pressure least 180 mmHg sit diastolic blood pressure least 100 mmHg ) Proliferative retinopathy macular oedema require acute treatment Metformin contraindication accord package insert Current treatment systemic corticosteroid Subject history illness , opinion investigator , might confound result study pose additional risk administer study drug subject Current addiction alcohol addictive substance determine Investigator Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation study use glucose monitor History hypoglycaemic unawareness and/or two severe hypoglycaemic episode past year judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>